Pain Management

$80 million agreement to bring pain control agent to European market signed

Published in Clinical Oncology Week, May 16th, 2005

SkyePharma PLC (SKYE) announced that it has entered into a strategic development and marketing arrangement with Mundipharma International Holdings Limited for the marketing and distribution of DepoBupivacaine in Europe and other international markets excluding the U.S., Canada and Japan.

Mundipharma is already SkyePharma's European marketing partner for the cancer treatment DepoCyte.

Under the agreement with Mundipharma, SkyePharma will receive $10 million on signature, most of which will be deferred and recognized to income to cover the cost of the phase 2 clinical trials. SkyePharma will also receive further contributions of up to US$20 million...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2005-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry